-
Every so often, one runs across a paper that is somewhat offbeat, but could have some beneficial clinical implications. One such article appeared recently in the British Journal of Obstetrics and Gynecology that dealt with a way to possibly counter the fetal effects of maternal hyperthermia and even protect the brains of fetuses/infants against potential hypoxic insult during labor.
-
Through the contraceptive choice project, the authors performed a prospective cohort study in which 9256 women living in the region surrounding St. Louis, Missouri, received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
-
Managing chronic pain is a challenge for patients and clinicians alike, with 52% of chronic pain patients being treated solely by their primary care physician.1 Chronic myofascial pain affects 116 million American adults, which is more than heart disease, cancer, and diabetes combined.2
-
-
Medically self-sabotaging behavior encompasses a number of diverse phenomena that include factitious disorder, making medical situations worse on purpose, and preventing wounds from healing.
-
Beta-Blocker Use in Situations Other than Just Post-MI; Long-Term Sexual and Psychological Adverse Effects of Finasteride; Novel CV Risk Markers: How Much Cluck for the Buck?
-
-
After careful evaluation of all the published studies regarding the possible adverse effects of statin therapy, Jukema et al have concluded that there is no proven increased risk of cognitive decline or cancer development. However, there is a possible small increased risk for the development of type 2 diabetes mellitus.
-
A new androgen receptor antagonist has been approved for the treatment of late-stage prostate cancer. Enzalutamide was approved 3 months ahead of schedule due to a priority review by the FDA. The drug is comarketed by Astellas Pharma and Medivation as Xtandi.